<DOC>
	<DOCNO>NCT01099124</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerance M2ES TC regimen advance NSCLC .</brief_summary>
	<brief_title>Study M2ES With Paclitaxel/Carboplatin ( TC Regimen ) Advanced Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Aged 1870 year old ; 2 . Patients Ⅲ/Ⅳ NSCLC confirm histopathology cytology ware naive previous chemotherapy without TC regimen ; 3 . No contraindication chemotherapy ; 4 . ECOG performance scale 02 ; 5 . No history antiangiogenesis therapy ; 6 . Patients voluntary participate sigh inform content . 1 . Concurrent use anticancer agent ; 2 . Allergic history M2ES biological agent ; 3 . Pregnant breastfeeding woman ; 4 . With malignancy ; 5 . With severe cardiopulmonary disease ; 6 . Uncontrolled brain metastasis patient ; 7 . Other condition regard exclusion trialists .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>M2ES</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Phase I Trial</keyword>
	<keyword>Advanced NSCLC</keyword>
	<keyword>Recurrent NSCLC</keyword>
</DOC>